The Kidney in Fabry Disease: More Than Mere Sphingolipids Overload

Abstract

Fabry disease is a rare cause of end-stage renal disease. Renal pathology is notable for diffuse deposition of glycosphingolipid in the renal glomeruli, tubules, and vasculature. Classical patients with mutations in the α-galactosidase A gene accumulate globotriaosylceramide and become symptomatic in childhood with pain, gastrointestinal disturbances, angiokeratoma, and hypohidrosis. Classical patients experience progressive loss of renal function and hypertrophic cardiomyopathy, with severe clinical events including end-stage renal disease, stroke, arrhythmias, and premature death. The pathophysiological mechanisms by which endothelial cells, podocytes, smooth muscle cells, and tubular dysfunction occur in Fabry disease are poorly characterized and understood. This review evaluates the new evidence in pathophysiology of Fabry nephropathy, highlighting the necessity of early identification of individuals with Fabry disease.

Keywords
Fabry disease; globotriaosylceramide; podocyte; nitric oxide; angiotensin II

Introduction

Fabry disease is an X-linked genetic disorder of glycosphingolipid catabolism resulting from deficient activity of the lysosomal enzyme α-galactosidase A (α-gal A). As a consequence, the substrates of α-gal A, which are neutral glycosphingolipids, mainly globotriaosylceramide (Gl3) and lyso-Gl3, accumulate in a variety of cells and tissues, leading to a wide clinical spectrum of clinical manifestations.¹-³ At the cellular level, the endothelium, podocytes, tubular cells, vascular smooth muscle cells, and mesangial cells are simultaneously affected. As a result, the glomerular basement membrane, vessels, and interstitium are gradually and progressively involved, resulting in proteinuria and progressive renal dysfunction. Chronic kidney disease is a prominent feature of Fabry disease that accounts for 0.01% of European and US dialysis registries.¹,²-⁶ However, enzymatic screening studies suggest that the true prevalence for male dialysis patients may be 10- to 100-fold higher.⁷,⁸ Glomerular basement membrane damage can be observed either at the podocyte or at the endothelial side. However, the pathophysiological mechanisms by which endothelial cells, podocytes, smooth muscle cells, and tubular dysfunction occur in Fabry disease are poorly characterized and understood.³,⁹

Vascular Compromise

The classic suggested vascular mechanisms of renal injury in Fabry disease include an initial compromise due to deposition of Gl3 in the endothelium and within the arterial wall, mainly in smooth muscle cells. This Gl3 and lyso-Gl3 accumulation in the endothelium leads to a secondary decrease in nitric oxide (NO) synthesis and a trend to microthrombotic events that lead to local ischemic events. In this regard, 2 primary hypotheses have emerged to explain the pathogenesis of this vasculopathy. The first hypothesis states that circulating lyso-Gl3 deposits in the medial layer of the arterial vasculature stimulate smooth muscle cell proliferation and remodeling of the subendothelial compartment. The increase in shear stress results in an augmented expression of angiotensin receptors with the secondary formation of reactive oxygen species and nuclear factor kappa B activation. All these changes cause a decrease in NO synthesis and increase in β-integrin subunits expression.¹⁰ An alternative but not contradictory hypothesis proposes that endothelial NO synthase (eNOS) dysregulation is the initial step for the development of Fabry-associated vasculopathy and that the Gl3 accumulation in the endothelium alone is sufficient to account for the dysregulation of eNOS. This phenomenon results in a lower NO bioavailability and eNOS uncoupling with the formation of reactive oxidants. These observations were consistent with a role for Gl3 in the assembly of the signalosome within the cytoplasmatic caveolae, including eNOS. These experimental models of thrombosis, atherogenesis, and impaired relaxation underscore the role eNOS dysregulation plays as a fundamental basis for the inducible models of vasculopathy in Fabry disease. Clinical studies have been less consistent with the primary role NO may play in this scenario but support a critical role for eNOS dysregulation.¹¹-¹⁵ Shu et al have recently shown that in Fabry disease, levels of 3-nitrotyrosine, a specific marker for reactive nitrogen species, increased by 40- to 120-fold without corresponding changes in other oxidized amino acids, consistent with eNOS-derived reactive nitrogen species as the source of oxygen reactants. In conclusion, 3-nitrotyrosine may serve as a biomarker for the vascular involvement in Fabry disease.¹⁶

Podocyte Mass

Parallel to the above-mentioned vascular compromise, a crucial event takes place. While endothelial and vascular smooth muscle cell damage leads to vasoconstriction and hypoxia, irreversible podocyte injury and detachment potentiate this progression to renal failure with the resultant glomerulosclerosis.¹⁷,¹⁸

The mechanisms of podocyte detachment are caused by the accumulation of Gl3, which interacts with podocyte cytoplasmic actin causing cell contraction, slit diaphragm widening, and the coupling with integrins. In this regard, α_vβ₃ integrin and α₃β₁ are some of the main molecules that anchor podocytes to the basement membrane. In Fabry disease, when the α_vβ₃ becomes activated, it triggers podocytic contraction and migration, finally contributing to podocyte detachment from the glomerulus and podocyturia.¹⁹,²⁰ Noteworthy, Utsumi et al have found elevated levels of α_vβ₃ integrin in the urine of individuals with Fabry disease, probably due to the accumulation of Gl3. The augmented localization of the β₃ component was seen mainly in podocytes and in epithelial cells of Bowman capsule.²⁰ Finally, the amount of vitronectin (a molecule involved in adhesion and fibrinolysis) was moderately increased in the kidney in patients with Fabry disease.²⁰ This finding is very interesting, as vitronectin couples with the urokinase–plasminogen activator receptor (uPAR). The uPAR actively participates in podocyte signal transduction via the α₃β₁ integrin, which in turn interacts with actin to cause podocyte contraction.²¹,²²-²⁶ Therefore, in Fabry disease, the activation of certain integrins appears to be actively involved in podocyte detachment from the glomerular basement membrane.²⁰,²²-²⁷ With respect to the progression of kidney disease and proteinuria, in vitro studies of Fabry-cultured human podocytes have shown that the accumulation of Gl3 or lyso-Gl3 stimulated the secretion of transforming growth factor β1 and fibrosis.²⁷,²⁸ Moreover, autophagy is dysregulated in Fabry podocytes due to the inhibition of mammalian target of rapamycin (mTOR), a key enzyme that inhibits autophagy.²⁹ The accumulation of Gl3 and autophagosomes and a loss of mTOR kinase activity may indicate that autophagy may be an additional mechanism to podocyte depletion and proteinuria.²⁹ Finally, angiotensin II also plays a role in podocyte damage due to the fact that podocytes contain angiotensin II receptors. Angiotensin II leads to podocyte hypertrophy, stimulates transforming growth factor β1 synthesis, and depolymerizes podocyte actin, causing a deep disorganization of the cytoskeleton. The addition of converting enzyme inhibitors or angiotensin receptor blockers reduces podocyturia and proteinuria, as they are capable of decreasing podocyte contraction and also reducing the size pores of the glomerular basement membrane and the width of the slit diaphragms.³⁰

In this respect, despite proteinuria is a useful marker of kidney disease and of glomerular injury, it is not specific of the stage of kidney damage, as it can be found at any stage of chronic kidney disease. Albeit a specific treatment for the disease exists, proteinuria frequently persists, particularly as renal disease worsens.¹⁷ However, an excessive loss of podocytes in the urine could have been indicating an established structural glomerular abnormality and would herald the ulterior appearance of proteinuria. In addition, as podocytes do not replicate, once podocytes are detached from the glomerular basement membrane, the filtration barrier becomes denuded and proteinuria ensues when contiguous podocytes are unable to cover the function of the lost ones. It has been reported that when the population of podocytes per glomerulus is reduced to 20% to 40%, the process of glomerular obliteration is initiated.³¹,³² Finally, it has been calculated that around 400 podocytes are lost in the urine everyday, which explains that the control patient also presents with podocyturia but of lower quantity.³¹,³²

Tubular Aspects

Tubular damage is mainly caused by the ischemic disturbances secondary to the vascular accumulation of Gl3 and lyso-Gl3 within the arterial wall, coupled with the podocyte loss and glomerulosclerosis, which determine the irreversible picture of tubular atrophy and interstitial fibrosis.¹⁷ In addition, the tubular accumulation of sphingolipids within their cytoplasm translates into different electrolyte disturbances according to the involved segment of the nephron. For instance, Gl3 is mainly expressed in the proximal tubules with concomitant expression of angiotensin-converting enzyme. This finding may suggest that Gl3 and angiotensin II could be normally implicated in sodium and bicarbonate homeostasis.³³

The Inflammatory Milieu

The renal sphingolipid overload leads to a reactive local inflammatory response. The parenchymal renin–angiotensin system and steroid-dependent inflammatory pathways must be involved in Fabry disease.⁹ To our knowledge, many biomarkers are elevated in Fabry disease with glomerulosclerotic implications that explain a response to steroid therapy. The expression levels of renal thrombospondin 1, transforming growth factor β1, vascular endothelial growth factor, and fibroblast growth factor 2 are higher in kidneys of Fabry mice compared to wild-type mice. Activities of caspases are also higher in kidneys of Fabry mice. These results may suggest that overexpression of transforming growth factor β1 and vascular endothelial growth factor in the Fabry mouse kidney might contribute to Fabry glomerulosclerosis by inducing fibrosis and apoptosis.³ Expression of thrombospondin 1 is increased in progressive renal disease and is associated with renal fibrosis and stimulates transforming growth factor β1 in diabetes. Thrombospondin 1 is a possible activator of transforming growth factor β1 in kidney injury and can induce apoptosis of endothelial cells. In addition, vascular endothelial growth factor increases vascular permeability, prevents apoptosis in endothelial cells, and induces apoptosis in cerebral endothelial cells after cell injury. It has been suggested that transforming growth factor β1 activates expression of fibroblast growth factor 2 in endothelial cells, which then promotes vascular endothelial growth factor production, and vascular endothelial growth factor–induced fibroblast growth factor 2 expression in injured endothelial cells leads to migration and proliferation of smooth muscle cells. Vascular endothelial growth factor stimulation results in transforming growth factor β1-induced fibrosis in proximal tubular cells. Upregulation of transforming growth factor β1 and vascular endothelial growth factor may be associated with dysfunction of endothelial cells. Similarly, Sanchez-Niαo et al reported that the expression of transforming growth factor β1, CD74, and extracellular matrix protein were increased by adding Lyso-GL3 to human podocytes, showing that transforming growth factor β1 and CD74 are mediators of podocyte injury.²⁸ CD74, the macrophage inhibitory factor receptor, is a potent receptor of kidney injury in diabetic nephropathy and sclerotic lesions. Increased expression of transforming growth factor β1 and/or vascular endothelial growth factor in podocytes is associated with apoptosis or nephropathy.³ Finally, Gl3 correlates with oxidative stress and inflammation in Fabry disease. Patients presented decreased levels of antioxidant defenses, reduced glutathione, reduced glutathione peroxidase activity, increased superoxide dismutase–catalase ratio in erythrocytes, and interleukin 6 and tumor necrosis factor α increments.³⁴ However, other studies show a decrease in tumor necrosis factor α.³⁵ Decreased α-2-antiplasmin was also associated with a parallel increase in circulating vascular endothelial growth factor and contributing to prothrombotic events in Fabry disease.¹⁰ Sclerotic and thrombotic events can certainly contribute to ischemia and hypoperfusion, eventually leading to renal insufficiency. All these biomarkers and cytokines have been described to be elevated in focal and segmental glomerulosclerosis³⁶,³⁷ and may explain the response to low-dose steroid therapy that exceptionally patients with Fabry may require as adjunctive therapy.

Angiotensin II: A Link Between Inflammation and Hypoxia in Fabry Disease

Interestingly, besides the well-known roles of angiotensin II in vasoconstriction, inflammation, and fibrosis, it is also involved in the pathogenesis of Fabry disease. Angiotensin-converting enzyme, a pivotal component of the renin–angiotensin system that converts angiotensin I to angiotensin II, is expressed in the plasma membrane of vascular endothelial cells, epithelial cells of renal proximal tubules, gastrointestinal tract, heart, and in various regions of the brain, the main tissues affected in Fabry disease.³⁸ It appears that treatment with recombinant α-gal A decreases angiotensin-converting enzyme activity probably mediated by the release of the galactose residues from the angiotensin-converting enzyme molecule. The degree of angiotensin-converting enzyme glycosylation is important for the catalytic properties of the enzyme. In addition, glycosylation plays an important role in the release of angiotensin-converting enzyme from the membrane. Interestingly, 2 weeks later, angiotensin-converting enzyme activity was significantly upregulated, and the plasma levels of angiotensin II increased in the patients treated with α-gal A following the elevations in activity of angiotensin-converting enzyme.³⁸ Proteinuria, which has emerged as an important risk factor for progression of kidney disease and considered the most important biomarker of disease progression in Fabry nephropathy, does not respond to enzyme replacement therapy alone using either recombinant agalsidase-α or recombinant agalsidase-β.³⁹ In this regard, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy has been shown to be effective in lowering proteinuria in Fabry disease as an adjunctive therapy.⁴⁰,⁴¹

The Implications of the Enzyme Mutation Involved

Only to be mentioned, the inflammatory cytokine patterns of expression in Fabry disease may be subjected to the polymorphisms and mutations encountered and may be independent of the levels of α-gal A.³⁵ An example to this phenomenon could be the reported different levels of tumor necrosis factor α in patients with Fabry disease,³⁴,³⁵ although it could also be due to the stage of the disease under consideration.⁹

Funding

• The author(s) received no financial support for the research, authorship, and/or publication of this article.

References

• ¹
  Desnick, RJ, Ioannou, Y, Eng, CM. α-Galactosidase A deficiency: Fabry disease. In: Scriver, CR, Beaudet, AL, Sly, WS, Valle, D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 2001:3733–3774.
• ²
  Warnock, DJ . Fabry disease: diagnosis and management, with emphasis on the renal manifestations. Curr Opin Nephrol Hypertens. 2005;14(2):87–95.
• ³
  Lee, MH, Choi, EN, Jeon, YJ, Jung, SC. Possible role of transforming growth factor-?1 and vascular endothelial growth factor in Fabry disease nephropathy. Int J Mol Med. 2012;30(6):1275–1280.
• ⁴
  Branton, MH, Schiffmann, R, Sabnis, SG. Natural history of Fabry renal disease: influence of α-galactosidase a activity and genetic mutations on clinical course. Medicine (Baltimore). 2002;81(2):122–138.
• ⁵
  Tsakiris, D, Simpson, HK, Jones, EH. Report on management of renal failure in Europe-XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant. 1996;11(suppl 7):4–20.
• ⁶
  Thadhani, R, Wolf, M, West, ML. Patients with Fabry disease on dialysis in the United States. Kidney Int. 2002;61(1):249–255.
• ⁷
  Nakao, S, Kodama, C, Takenaka, T. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype. Kidney Int. 2003;64(3):801–807.
• ⁸
  Kotanko, P, Kramar, R, Devrnja, D. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol. 2004;15(5):1323–1329.
• ⁹
  Trimarchi, H, Karl, A, Raαa, MS. Initially Non-diagnosed Fabry’s Disease when Electron Microscopy Is Lacking: The Continuing Story of Focal and Segmental Glomerulosclerosis. Case Rep Nephrol Urol. 2013;3(1):51–57.
• ¹⁰
  Rombach, SM, Twickler, TB, Aerts, JM, Linthorst, GE, Wijburg, FA, Hollak, CE. Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol Genet Metab. 2010;99(2):99–108.
• ¹¹
  Shen, JS, Meng, XL, Moore, DF. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab. 2008;95(3):163–168.
• ¹²
  Bodary, PF, Shen, Y, Vargas, FB. Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation. 2005;111(5):629–632.
• ¹³
  Park, JL, Whitesall, SE, D’Alecy, LG, Shu, L, Shayman, JA. Vascular dysfunction in the alphagalactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect. Clin Exp Pharmacol Physiol. 2008;35(10):1156–1163.14.Shu, L, Shayman, JA. Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of alphagalactosidase A null mice. J Biol Chem. 2007;282(29):20960–20967.
• ¹⁴
  Shu, L, Shayman, JA. Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of alphagalactosidase A null mice. J Biol Chem. 2007;282(29):20960–20967.
• ¹⁵
  Shu, L, Shayman, JA. Glycosphingolipid mediated caveolin-1 oligomerization. J Glycomics Lipidomics. 2012;suppl 2:1–6.
• ¹⁶
  Shu, L, Vivekanandan-Giri, A, Pennathur, S. Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease. Kidney Int. 2014;86(1):58–66.
• ¹⁷
  Najafian, B, Svarstad, E, Bostad, L. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney Int. 2011;79(6):663–670.
• ¹⁸
  Trimarchi, H. Podocyturia. What is in a name? J Translat Internal Med. 2015;3(2):51–56.
• ¹⁹
  Fornoni, A, Merscher, S, Kopp, JB. Lipid biology of podocyte-new perspectives offer new opportunities. Nat Rev Nephrol. 2014;10(7):379–388.
• ²⁰
  Utsumi, K, Itoh, K, Kase, R. Urinary excretion of the vitronectin receptor (integrin α_V ?₃) in patients with Fabry disease. Clin Chim Acta. 1999;279(1-2):55–68.
• ²¹
  Trimarchi, H, Forrester, M, Lombi, F. Amiloride as an alternate adjuvant antiproteinuric agent in Fabry disease. The potential roles of plasmin and uPAR. Case Rep Nephrol. 2014;2014:854521.
• ²²
  Trimarchi, H . Plasmin, urokinase plasminogen activator receptor and amiloride in the nephrotic syndrome. In: Mubarak, M , ed. Nephrotic Syndrome. Etiology, Pathogenesis and Pathology. New York, NY: Nova Biomedical; 2015:11–28.
• ²³
  Chapman, HA, Wei, Y. Protease crosstalk with integrins: the urokinase receptor paradigm. Thromb Haemost. 2001;86(1):124–129.
• ²⁴
  Wei, C, Möller, CC, Altintas, MM. Modification of kidney barrier function by the urokinase receptor. Nat Med. 2008;14(1):55–63.
• ²⁵
  Regoli, M, Bendayan, M. Alterations in the expression of the alpha 3 beta 1 integrin in certain membrane domains of the glomerular epithelial cells (podocytes) in diabetes mellitus. Diabetologia. 1997;40(1):15–22.
• ²⁶
  Sachs, N, Sonnenberg, A. Cell-matrix adhesion of podocytes in physiology and disease. Nat Rev Nephrol. 2013;9(4):200–210.
• ²⁷
  Trimarchi, H, Canzonieri, R, Muryan, A. Copious podocyturia without proteinuria and with normal renal function in a young adult with Fabry disease. Case Rep Nephrol. 2015;2015:257628.
• ²⁸
  Sanchez-Niαo, MD, Sanz, AB, Carrasco, S. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol Dial Transplant. 2011;26(6):1797–1802.
• ²⁹
  Liebau, MC, Braun, F, Höpker, K. Dysregulated autophagy contributes to podocyte damage in Fabry’s disease. PLoS One. 2013;8(5):e63506.
• ³⁰
  Müller-Deile, J, Schiffer, M. Podocyte directed therapy of nephrotic syndrome-can we bring the inside out? Pediatr Nephrol. 2016;31(3):393–405. doi:10.1007/s00467-015-3116-4.
  » https://doi.org/10.1007/s00467-015-3116-4
• ³¹
  Vogelmann, SU, Nelson, WJ, Myers, BD, Lemley, KV. Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol. 2003;285(1):f40–f48.
• ³²
  Wharram, BL, Goyal, M, Wiggins, JE. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol. 2005;16(10):2941–2952.
• ³³
  Fujii, Y, Numata, S, Nakamura, Y. Murine glycosyltransferases responsible for the expression of globo-series glycolipids: cDNA structures, mRNA expression, and distribution of their products. Glycobiology. 2005;15(12):1257–1267.
• ³⁴
  Biancini, GB, Vanzin, CS, Rodrigues, DB. Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy. Biochim Biophys Acta. 2012;1822(2):226–232.
• ³⁵
  Safyan, R, Whybra, C, Beck, M, Elstein, D, Altarescu, G. An association study of inflammatory cytokine gene polymorphisms in Fabry disease. Eur Cytokine Netw. 2006;17(4):271–275.
• ³⁶
  Yang, W, Wang, J, Shi, L. Podocyte injury and overexpression of vascular endothelial growth factor and transforming growth factor-beta 1 in adriamycin-induced nephropathy in rats. Cytokine. 2012;59(2):370–376.
• ³⁷
  Lee, HS . Mechanisms and consequences of TGF-Ÿ overexpression by podocytes in progressive podocyte disease. Cell Tissue Res. 2012;347(1):129–140.
• ³⁸
  Batista, EC, Carvalho, LR, Casarini, DE. ACE activity is modulated by the enzyme α-galactosidase A. J Mol Med (Berl). 2011;89(1):65–74.
• ³⁹
  Schiffmann, R, Waldek, S, Benigni, A, Auray-Blais, C. Biomarkers of Fabry disease nephropathy. Clin J Am Soc Nephrol. 2010;5(2):360–364.
• ⁴⁰
  Torra, S . Renal manifestations in Fabry disease and therapeutic options. Kidney Int. 2008;74:(suppl 111):s29–s32.
• ⁴¹
  Tahir, H, Jackson, LL, Warnock, DG. Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-?. J Am Soc Nephrol. 2007;18(9):2609–2617

Publication Dates

• Publication in this collection
  30 May 2019
• Date of issue
  2016

History

• Received
  13 Feb 2016
• Accepted
  22 Mar 2016